
CHMP approve Bristol-Myers Squibb’s Sprycel for paediatric patients with Ph+ ALL
pharmafile | December 17, 2018 | News story | Sales and Marketing |ย ย BMS, Bristol-Myers Squibb, Cancer, Sprycel, allย
New Jersey-based firm Bristol -Myers Squibb today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the expanded approval of Sprycel (dasatinib), in combination with chemotherapy for the treatment of paediatric patients (Ph+) acute lymphoblastic leukemia (ALL).
The powder form of Sprycel, which allows patients with an inability to swallow tablets to suspnd the medicines in water, was first approved by the European Commission in July 2018.
โWe are pleased with todayโs CHMP recommendation for Sprycel in pediatric patients with Ph+ ALL, and look forward to the possibility of expanding Sprycelโs pediatric indications in the EU to include young patients with this particularly high-risk leukemia,โ said Fouad Namouni, M.D., head, oncology development, Bristol-Myers Squibb.
Louis Goss
Related Content

Central nervous system cancer metastases โ the evolution of diagnostics and treatment
The current forms of immunotherapy, how T cell therapy works and what the future holds

BioMed X and Servier launch Europeโs first XSeed Labs to advance AI-powered antibody design
BioMed X and Servier have announced the launch of Europeโs first XSeed Labs research project, …

T-cell therapy โ the evolution of cancer treatments
The current forms of immunotherapy, how T cell therapy works and what the future holds






